The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Personalized medicine could transform healthcare
Open accessAbstract
Personalized medicine (PM) is about tailoring a treatment as individualized as the disease. The approach relies on identifying genetic, epigenomic, and clinical information that allows the breakthroughs in our understanding of how a person's unique genomic portfolio makes them vulnerable to certain diseases. PM approach is a complete extension of traditional approach (One-Size-Fits-All) to increasing our ability to predict which medical treatments will be safe and effective for individual patient, and which ones will not be, based on the patient's unique genetic profile. Implementation of PM has the potential to reduce financial and time expenditure, and increase quality of life and life extension of patients. Knowledge of PM facilitates earlier disease detection via enhanced use of existing biomarkers and detection of early genomic and epigenomic events in disease development, particularly carcinogenesis. The PM approach predominantly focuses on preventative medicine and favours taking pro-active actions rather than just reactive. This approach delays or prevents the need to apply more severe treatments which are usually less tolerated and with increased quality of life and financial considerations. Increasing healthcare costs have placed additional pressure on government funded healthcare systems globally, especially regarding end of life care. PM may increase the effectiveness of existing treatments and negate the inherent problems associated with non-PM approaches. PM is a young but rapidly expanding field of healthcare where a physician can select a treatment based on a patient's genetic profile that may not only minimize harmful side effects and guarantee a more successful result, but can be less cost effective compared with a 'trial-and-error' approach to disease treatment. The less efficient non-PM ('trial-and-error') approach, which can lead to drug toxicity, severe side effects, reactive treatment and misdiagnosis continue to contribute to increasing healthcare costs. Increased patient stratification will allow for the enhanced application of PM and pro-active treatment regimens, resulting in reduced costs and quality of life enhancement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
The Path to Personalized Medicine
Hamburg, M. A., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006304 · Cited by 1,970
Cas9 as a versatile tool for engineering biology
Mali, P., Esvelt, K. M., & Church, G. M. (2013) · Nature Methods · doi:10.1038/nmeth.2649 · Cited by 1,197
Khoury, M. J., Gwinn, M., Yoon, P. W., Dowling, N., Moore, C. A., & Bradley, L. (2007) · Genetics in Medicine · doi:10.1097/gim.0b013e31815699d0 · Cited by 705
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
Vu, T., & Claret, F. X. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00062 · Cited by 606
CRISPR gene-editing tested in a person for the first time
Cyranoski, D. (2016) · Nature · doi:10.1038/nature.2016.20988 · Cited by 362
Hood, L., & Galas, D. (2003) · Nature · doi:10.1038/nature01410 · Cited by 274
Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study
Jamal-Hanjani, M., Hackshaw, A., Ngai, Y., Shaw, J., Dive, C., Quezada, S., Middleton, G., de Bruin, E., Le Quesne, J., Shafi, S., et al. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001906 · Cited by 247
Pharmacogenetics/genomics and personalized medicine
Sadée, W., & Dai, Z. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi261 · Cited by 227
Personalized medicine: part 1: evolution and development into theranostics.
Vogenberg, F. R., Barash, C. I., & Pursel, M. (2010) · PubMed · Cited by 198
Cited by
Wearable Electrochemical Sensors for the Monitoring and Screening of Drugs
Teymourian, H., Parrilla, M., Sempionatto, J. R., Montiel, N. F., Barfidokht, A., Van Echelpoel, R., De Wael, K., & Wang, J. (2020) · ACS Sensors · doi:10.1021/acssensors.0c01318 · Cited by 423
From hype to reality: data science enabling personalized medicine
Fröhlich, H., Balling, R., Beerenwinkel, N., Kohlbacher, O., Kumar, S., Lengauer, T., Maathuis, M. H., Moreau, Y., Murphy, S. A., Przytycka, T. M., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1122-7 · Cited by 414
3D Printing as a Promising Tool in Personalized Medicine
Vaz, V. M., & Kumar, L. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-020-01905-8 · Cited by 409
Data Integration Challenges for Machine Learning in Precision Medicine
Martínez-García, M., & Hernández-Lemus, E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.784455 · Cited by 185
Artificial Intelligence in Regenerative Medicine: Applications and Implications
Nosrati, H., & Nosrati, M. (2023) · Biomimetics · doi:10.3390/biomimetics8050442 · Cited by 158
Metadata
- Authors
- Mathur, S., & Sutton, J.
- Venue
- Biomedical Reports
- Publisher
- Spandidos Publications
- Published
- 2017-06-02
- Volume
- 7
- Issue
- 1
- Pages
- 3-5
- ISSN
- 2049-9434 (ISSN-L)
- 2049-9442
- OpenAlex
- W2620804920
- Cited by
- 388
- References
- 16
- FWCI
- 14.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Personalized medicine could transform healthcare. https://app.cochat.ai/papers/10.3892/br.2017.922
- The paper
- Mathur, S., & Sutton, J. (2017). Personalized medicine could transform healthcare. Biomedical Reports. https://doi.org/10.3892/br.2017.922
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.